|
1
|
Conese M and Blasi F: The
urokinase/urokinase-receptor system and cancer invasion. Baillieres
Clin Haematol. 8:365–389. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rakic JM, Maillard C, Jost M, et al: Role
of plasminogen activator-plasmin system in tumor angiogenesis. Cell
Mol Life Sci. 60:463–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slot O, Brünner N, Locht H, Oxholm P and
Stephens RW: Soluble urokinase plasminogen activator receptor in
plasma of patients with inflammatory rheumatic disorders: increased
concentrations in rheumatoid arthritis. Ann Rheum Dis. 58:488–492.
1999. View Article : Google Scholar
|
|
4
|
Stoppelli MP, Tacchetti C, Cubellis MV, et
al: Autocrine saturation of pro-urokinase receptors on human A431
cells. Cell. 45:675–684. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lijnen HR, Maquoi E, Hansen LB, Van Hoef
B, Frederix L and Collen D: Matrix metalloproteinase inhibition
impairs adipose tissue development in mice. Arterioscler Thromb
Vasc Biol. 22:374–379. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Andreasen PA, Egelund R and Petersen HH:
The plasminogen activation system in tumor growth, invasion, and
metastasis. Cell Mol Life Sci. 57:25–40. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Andreasen PA, Kjøller L, Christensen L and
Duffy MJ: The urokinase-type plasminogen activator system in cancer
metastasis: a review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blasi F: uPA, uPAR, PAI-1: key
intersection of proteolytic, adhesive and chemotactic highways?
Immunol Today. 18:415–417. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sitrin RG, Todd RF III, Albrecht E and
Gyetko MR: The urokinase receptor (CD87) facilitates
CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest.
97:1942–1951. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stefansson S and Lawrence DA: The serpin
PAI-1 inhibits cell migration by blocking integrin alpha V beta 3
binding to vitronectin. Nature. 383:441–443. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ginsburg D, Zeheb R, Yang AY, et al: cDNA
cloning of human plasminogen activator-inhibitor from endothelial
cells. J Clin Invest. 78:1673–1680. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chorostowska-Wynimko J, Skrzypczak-Jankun
E and Jankun J: Plasminogen activator inhibitor type-1: Its
structure, biological activity and role in tumorigenesis (Review).
Int J Mol Med. 13:759–766. 2004.PubMed/NCBI
|
|
13
|
Stefansson S, McMahon GA, Petitclerc E and
Lawrence DA: Plasminogen activator inhibitor-1 in tumor growth,
angiogenesis and vascular remodeling. Curr Pharm Des. 9:1545–1564.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamamoto K and Saito H: A pathological
role of increased expression of plasminogen activator inhibitor-1
in human or animal disorders. Int J Hematol. 68:371–385. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chorostowska-Wynimko J, Swiercz R,
Skrzypczak-Jankun E, Wojtowicz A, Selman SH and Jankun J: A novel
form of the plasminogen activator inhibitor created by cysteine
mutations extends its half-life: relevance to cancer and
angiogenesis. Mol Cancer Ther. 2:19–28. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jankun J, Yang J, Zheng H, Han FQ,
Al-Senaidy A and Skrzypczak-Jankun E: Remarkable extension of PAI-1
half-life surprisingly brings no changes to its structure. Int J
Mol Med. 29:61–64. 2012.PubMed/NCBI
|
|
17
|
Berkenpas MB, Lawrence DA and Ginsburg D:
Molecular evolution of plasminogen activator inhibitor-1 functional
stability. EMBO J. 14:2969–2977. 1995.PubMed/NCBI
|
|
18
|
Tucker HM, Mottonen J, Goldsmith EJ and
Gerard RD: Engineering of plasminogen activator inhibitor-1 to
reduce the rate of latency transition. Nat Struct Biol. 2:442–445.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dano K, Andreasen PA, Grondahl-Hansen J,
Kristensen P, Nielsen LS and Skriver L: Plasminogen activators,
tissue degradation, and cancer. Adv Cancer Res. 44:139–266. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Swiercz R, Keck RW, Skrzypczak-Jankun E,
Selman SH and Jankun J: Recombinant PAI-1 inhibits angiogenesis and
reduces size of LNCaP prostate cancer xenografts in SCID mice.
Oncol Rep. 8:463–470. 2001.PubMed/NCBI
|
|
21
|
Swiercz R, Skrzypczak-Jankun E, Merrell
MM, Selman SH and Jankun J: Angiostatic activity of synthetic
inhibitors of urokinase type plasminogen activator. Oncol Rep.
6:523–526. 1999.PubMed/NCBI
|
|
22
|
Jankun J, Aleem AM, Selman SH, et al:
Highly stable plasminogen activator inhibitor type one (VLHL PAI-1)
protects fibrin clots from tissue plasminogen activator-mediated
fibrinolysis. Int J Mol Med. 20:683–687. 2007.PubMed/NCBI
|
|
23
|
Jankun J, Aleem AM, Struniawski R,
Lysiak-Szydlowska W, Selman SH and Skrzypczak-Jankun E: Accelerated
thrombus lysis in the blood of plasminogen activator inhibitor
deficient mice is inhibited by PAI-1 with a very long half-life.
Pharmacol Rep. 61:673–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Klinghofer V, Stewart K, McGonigal T, et
al: Species specificity of amidine-based urokinase inhibitors.
Biochemistry. 40:9125–9131. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeslawska E, Jacob U, Schweinitz A, Coombs
G, Bode W and Madison E: Crystals of urokinase type plasminogen
activator complexes reveal the binding mode of peptidomimetic
inhibitors. J Mol Biol. 328:109–118. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao G, Yuan C, Wind T, Huang Z, Andreasen
PA and Huang M: Structural basis of specificity of a peptidyl
urokinase inhibitor, upain-1. J Struct Biol. 160:1–10. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Birn H and Fejerskov O: Fibrynolotic
activity of human oral epithelial cells: A preliminary report.
Scand J Dent Res. 79:381–386. 1971.PubMed/NCBI
|
|
28
|
Moody GH: The source of plasminogen
activator in human saliva. Archs Oral Biol. 27:33–37.
1982.PubMed/NCBI
|
|
29
|
Schmid J, Cohen RL and Chambers DA:
Plasminogen activator in human periodontal health and disease. Arch
Oral Biol. 36:245–250. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bartold PM, Walsh LJ and Narayanan AS:
Molecular and cell biology of the gingiva. Periodontol 2000.
24:28–55. 2000. View Article : Google Scholar
|
|
31
|
Schafer BM, Maier K, Eickhoff U, Todd RF
and Kramer MD: Plasminogen activation in healing human wounds. Am J
Pathol. 144:1269–1280. 1994.PubMed/NCBI
|
|
32
|
Xiao Y, Li H, Bunn C and Bartold PM: The
expression of plasminogen activator system in a rat model of
periodontal wound healing. J Periodontol. 72:849–857. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schaefer BM, Maier K, Eickhoff U, Bechtel
M and Kramer MD: alpha 2-Antiplasmin and plasminogen activator
inhibitors in healing human skin wounds. Arch Dermatol Res.
288:122–128. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thapa B, Kim YH, Kwon HJ and Kim DS: Novel
regulatory mechanism and functional implication of plasminogen
activator inhibitor-1 (PAI-1) expression in CpG-ODN-stimulated
macrophages. Mol Immunol. 49:572–581. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morimoto K, Mishima H, Nishida T and Otori
T: Role of urokinase type plasminogen activator (u-PA) in corneal
epithelial migration. Thromb Haemost. 69:387–391. 1993.PubMed/NCBI
|
|
36
|
Abiko Y, Arai J, Matsuzawa K, Inoue T,
Shimono M and Kaku T: Human gingival fibroblast migration promoted
by platelet-derived growth factor on titanium is correlated with
release of urokinase type plasminogen activator. Bull Tokyo Dent
Coll. 37:113–118. 1996.PubMed/NCBI
|
|
37
|
Horowitz JC, Rogers DS, Simon RH, Sisson
TH and Thannickal VJ: Plasminogen activation induced pericellular
fibronectin proteolysis promotes fibroblast apoptosis. Am J Respir
Cell Mol Biol. 38:78–87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Quigley JP, Gold LI, Schwimmer R and
Sullivan LM: Limited cleavage of cellular fibronectin by
plasminogen activator purified from transformed cells. Proc Natl
Acad Sci USA. 84:2776–2780. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Feghali K and Grenier D: Priming effect of
fibronectin fragments on the macrophage inflammatory response:
potential contribution to periodontitis. Inflammation.
35:1696–1705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yee JA, Yan L, Dominguez JC, Allan EH and
Martin TJ: Plasminogen-dependent activation of latent transforming
growth factor beta (TGF beta) by growing cultures of
osteoblast-like cells. J Cell Physiol. 157:528–534. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Allan EH and Martin TJ: The plasminogen
activator inhibitor system in bone cell function. Clin Orthop Relat
Res. 313:54–63. 1995.PubMed/NCBI
|
|
42
|
Daci E, Everts V, Torrekens S, et al:
Increased bone formation in mice lacking plasminogen activators. J
Bone Miner Res. 18:1167–1176. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bartold PM: Periodontal tissues in health
and disease: introduction. Periodontol 2000. 40:7–10. 2006.
View Article : Google Scholar
|
|
44
|
Bartold PM and Narayanan AS: Molecular and
cell biology of healthy and diseased periodontal tissues.
Periodontol 2000. 40:29–49. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kinnby B, Lecander I, Martinsson G and
Astedt BK: Tissue plasminogen activator and placental plasminogen
activator inhibitor in human gingival fluid. Fibrinolysis.
5:239–242. 1991. View Article : Google Scholar
|
|
46
|
Kinnby B, Matsson L and Lecander I: The
plasminogen-activating system in gingival fluid from adults. An
intra-individual study before and after treatment of gingivitis.
Scand J Dent Res. 102:334–341. 1994.PubMed/NCBI
|
|
47
|
Olofsson A, Lindberg P, Lanke J, Matsson L
and Kinnby B: Relationship between fibrinolytic activity and
gingival inflammatory reaction in young individuals. J Periodontal
Res. 38:104–108. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yin X, Bunn CL and Bartold PM: Detection
of tissue plasminogen activator (t-PA) and plasminogen activator
inhibitor 2 (PAI-2) in gingival crevicular fluid from healthy,
gingivitis and periodontitis patients. J Clin Periodontol.
27:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Olofsson A, Matsson L and Kinnby B:
Plasminogen activating capacity in gingival fluid from
deteriorating and stable periodontal pockets. J Periodontal Res.
37:60–65. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kinnby B, Lindberg P, Lecander I and
Matsson L: Localisation of plasminogen activator inhibitors in
human gingival tissue demonstrated by immunochemistry and in situ
hybridization. Arch Oral Biol. 44:1027–1034. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lindberg P, Kinnby B, Lecander I, Lang NP
and Matsson L: Increasing expression of tissue plasminogen
activator and plasminogen activator inhibitor type 2 in dog
gingival tissues with progressive inflammation. Arch Oral Biol.
46:23–31. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Papadimitriou S, Tsantarliotou M, Makris
G, et al: A clinical study of plasminogen activator activity in
gingival tissue in dogs with gingivitis and periodontitis. Res Vet
Sci. 80:189–193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bizzarro S, van der Velden U, ten Heggeler
JM, et al: Periodontitis is characterized by elevated PAI-1
activity. J Clin Periodontol. 34:574–580. 2007. View Article : Google Scholar
|
|
54
|
De Taeye B, Smith LH and Vaughan DE:
Plasminogen activator inhibitor-1: a common denominator in obesity,
diabetes and cardiovascular disease. Curr Opin Pharmacol.
5:149–154. 2005.PubMed/NCBI
|
|
55
|
Munford RS: Statins and the acute-phase
response. N Engl J Med. 344:2016–2018. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Agis H, Bauer M, Knebl G, Watzek G and
Gruber R: Effects of platelet-derived growth factor isoforms on
plasminogen activation by periodontal ligament and gingival
fibroblasts. J Periodontal Res. 43:334–342. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Haffajee AD and Socransky SS: Microbial
etiological agents of destructive periodontal diseases. Periodontol
2000. 5:78–111. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Uitto VJ, Larjava H, Heino J and Sorsa T:
A protease of Bacteroides gingivalis degrades cell surface
and matrix glycoproteins of cultured gingival fibroblasts and
induces secretion of collagenase and plasminogen activator. Infect
Immun. 57:213–218. 1989.
|
|
59
|
Oikawa T, Ogura N, Akiba M, Abiko Y,
Takiguchi H and Izumi H: Stimulation of plasmin activity in
cultured human fibroblast cells by Porphyromonas
endodontalis. Int J Biochem. 25:1227–1231. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ogura N, Shibata Y, Matsuda U, et al:
Effect of Campylobacter rectus LPS on plasminogen
activator-plasmin system in human gingival fibroblast cells. J
Periodontal Res. 30:132–140. 1995.
|
|
61
|
Mochan E, Armor L and Sporer R:
Interleukin 1 stimulation of plasminogen activator production in
cultured gingival fibroblasts. J Periodontal Res. 23:28–32. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sarajlic J, Agis H, Kandler B, Watzek G
and Gruber R: Plasminogen activation by fibroblasts from
periodontal ligament and gingiva is not directly affected by
chemokines in vitro. Arch Oral Biol. 52:663–668. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Birkedal-Hansen H: Role of matrix
metalloproteinases in human periodontal diseases. J Periodontol.
64:474–484. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Johnston KH: Solid and fluid phase assays
for bacterial plasminogen activators. J Microbiol Methods.
18:267–274. 1993. View Article : Google Scholar
|
|
65
|
Lottenberg R, Minning-Wenz D and Boyle MD:
Capturing host plasmin(ogen): a common mechanism for invasive
pathogens? Trends Microbiol. 2:20–24. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Pantzar M, Ljungh A and Wadstrom T:
Plasminogen binding and activation at the surface of Helicobacter
pylori CCUG 17874. Infect Immun. 66:4976–4980. 1998.PubMed/NCBI
|
|
67
|
Darenfed H, Grenier D and Mayrand D:
Acquisition of plasmin activity by Fusobacterium nucleatum
subsp nucleatum and potential contribution to tissue
destruction during periodontitis. Infect Immun. 67:6439–6444.
1999.PubMed/NCBI
|
|
68
|
Bennett KW and Eley A: Fusobacteria: new
taxonomy and related diseases. J Med Microbiol. 39:246–254. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Jankun J and Skrzypczak-Jankun E: Yin and
yang of the plasminogen activator inhibitor. Pol Arch Med Wewn.
119:410–417. 2009.PubMed/NCBI
|
|
70
|
Largent V, Deneys V, Brichard B, Chantrain
C and Vermylen C: Bleeding diathesis in a child with normal
screening tests: think about fibrinolysis. Eur J Pediatr.
164:587–588. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Mehta R and Shapiro AD: Plasminogen
activator inhibitor type 1 deficiency. Haemophilia. 14:1255–1260.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jankun J and Skrzypczak-Jankun E: Bleeding
diathesis is associated with an A15T heterozygous mutation in exon
2 of the plasminogen activator inhibitor type 1. Exp Ther Med.
1:575–577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Jankun J, Keck R, Selman SH and
Skrzypczak-Jankun E: Systemic or topical application of plasminogen
activator inhibitor with extended half-life (VLHL PAI-1) reduces
bleeding time and total blood loss. Int J Mol Med. 26:501–504.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
El-Darouti M, Zayed AA, El-Kamah GY and
Mostafa MI: Ligneous conjunctivitis with oral mucous membrane
involvement and decreased plasminogen level. Pediatr Dermatol.
26:448–451. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lin Z, Jiang L, Yuan C, et al: Structural
basis for recognition of urokinase-type plasminogen activator by
plasminogen activator inhibitor-1. J Biol Chem. 286:7027–7032.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zeslawska E, Schweinitz A, Karcher A, et
al: Crystals of the urokinase type plasminogen activator variant
beta(c)-uPAin complex with small molecule inhibitors open the way
towards structure-based drug design. J Mol Biol. 301:465–475. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Brown NJ: Therapeutic potential of
plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc
Dis. 4:315–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Xue Y, Björquist P, Inghardt T, et al:
Interfering with the inhibitory mechanism of serpins: crystal
structure of a complex formed between cleaved plasminogen activator
inhibitor type 1 and a reactive-centre loop peptide. Structure.
6:627–636. 1998. View Article : Google Scholar
|
|
79
|
Mavri A, Alessi MC, Bastelica D,
Geel-Georgelin O, et al: Subcutaneous abdominal, but not femoral
fat expression of plasminogen activator inhibitor-1 (PAI-1) is
related to plasma PAI-1 levels and insulin resistance and decreases
after weight loss. Diabetologia. 44:2025–2031. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ritchie CS: Obesity and periodontal
disease. Periodontol 2000. 44:154–163. 2007. View Article : Google Scholar
|
|
81
|
Saito T, Shimazaki Y, Koga T, et al:
Relationship between periodontitis and hepatic condition in
Japanese women. J Int Acad Periodontol. 8:89–95. 2006.PubMed/NCBI
|
|
82
|
Staufenbiel I, Weinspach K, Förster G, et
al: Periodontal condition in vegetarians: a clinical study. Eur J
Clin Nutr. 67:836–840. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Tanaka K, Sasaki S, Murakami K, et al:
Relationsip between soy and isoflavone intake and periodontal
disesae: the freshmen in dietetic Courses Study II. BMC Public
Health. 8:39–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Smith PC, Santibañez JF, Morales JP and
Martinez J: Epidermal growth factor stimulates urokinase-type
plasminogen activator expression in human gingival fibroblasts.
Possible modulation by genistein and curcumin. J Periodont Res.
39:380–387. 2004. View Article : Google Scholar
|
|
85
|
Kushiyama M, Shimazaki Y, Murakami M and
Yamashita Y: Relationship between intake of green tea and
periodontal disease. J Periodontol. 80:372–377. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Pasten C, Olave NC, Zhou L, et al:
Polyphenols downregulate PAI-1 gene expression in cultured human
coronary artery endothelial cells: molecular contributor to
cardiovascular protection. Thromb Res. 121:59–65. 2007. View Article : Google Scholar
|
|
87
|
Cho AR, Kim JH, Lee DE, et al: The effect
of orally administrated epigallocatechin-3-gallate on
ligature-induced periodontitis in rats. J Periodontol. 48:781–789.
2013.PubMed/NCBI
|
|
88
|
Hosokawa Y, Hosokawa I, Shindo S, et al:
(−)-Epigallocatechin-3-gallate inhibits CC chemokine ligand 11
production in human gingival fibroblasts. Cell Physiol Biochem.
31:960–967. 2013.
|
|
89
|
Guimarães MR, Coimbra LS, de Aquino SG, et
al: Potent anti-inflammatory effects of systemically administrated
curcumin modulate periodontal disease in vivo. J Periodontal Res.
46:269–279. 2011.PubMed/NCBI
|
|
90
|
Madhyastha R, Madhyastha H, Nakajima S, et
al: Curcumin facilitates fibrynolysis and cellular migration during
wound healing by modulation urokinase plasminogen activator
expression. Pathophysiol Haemost Thromb. 37:59–66. 2010. View Article : Google Scholar
|
